In the competitive healthcare landscape, Rede D’or’s stellar performance stands outs catching the eye of Goldman Sachs. Amidst a backdrop of struggling smaller hospitals, Rede D’or shines with impressive first-quarter results, indicating strength and resilience. Goldman Sachs acknowledges Rede D’or’s premium positioning, upgrading RDOR3 stock from neutral to buy, with a target increase to R$38. […]
